In Leqembi, what we've seen with p-tau181 is a stabilization. And actually, if you saw the donanemab data on p-217, which was the plasma tau biomarker they use, and these track really quite closely, is that you see a slight increase. So, I think we still need to understand, with more data transparency, the donanemab data of what really happens to patients who stopped at six months or stopped at one year. And we hope we'll see more of that data from their open-label extension and, you know, be able to draw conclusions.